As a subsidiary of Aditxt, Adimune continues to advance its novel immune modulation therapy, the ADI platform, for autoimmune diseases toward first-in-human clinical trials. Aditxt provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback